Ladenburg Thalmann Initiates Coverage On Calidi Biotherapeutics with Buy Rating, Announces Price Target of $1
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann has initiated coverage on Calidi Biotherapeutics (AMEX:CLDI) with a Buy rating and a price target of $1.
June 27, 2024 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ladenburg Thalmann has initiated coverage on Calidi Biotherapeutics with a Buy rating and a price target of $1.
The initiation of coverage with a Buy rating and a specific price target of $1 by Ladenburg Thalmann is likely to positively impact the stock price of Calidi Biotherapeutics in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100